医学
西妥昔单抗
贝伐单抗
肿瘤科
危险系数
结直肠癌
内科学
无进展生存期
癌症
化疗
置信区间
作者
Francesca Battaglin,Fang‐Shu Ou,Xueping Qu,Howard S. Höchster,Donna Niedzwiecki,Richard M. Goldberg,Robert J. Mayer,Karam Ashouri,Tyler Zemla,Charles D. Blanke,Alan P. Venook,Omar Kabbarah,Heinz‐Josef Lenz,Federico Innocenti
摘要
The phase III Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial found no difference in overall survival (OS) in patients with metastatic colorectal cancer receiving first-line chemotherapy in combination with either bevacizumab or cetuximab. We investigated the potential prognostic and predictive value of
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
Criminology34
大力的灵雁
David
无极微光
GingerF
BowieHuang
殷勤的紫槐
laber
干净的琦
愔愔
Tttttttt
tiptip
乐空思
zheei
Neo
寻道图强
hahah1
jyy
千空
伯克利芙蓉王
皖公网安备34019202002308
